Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 2/20 | 0.48 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.43 |
| ▸ | LDHA | P00338 | 4/20 | 0.42 |
| ▸ | LDHB | P07195 | 4/20 | 0.42 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.41 |
| ▸ | IGF1R | P08069 | 3/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3956498 | 1.00 | EGFR (0.48) | EGFRRPS6KB1LDHALDHBCRHR1 | |
| SCHEMBL4064799 | 1.00 | EGFR (0.48) | EGFRRPS6KB1LDHALDHBCRHR1 | |
| SCHEMBL3952919 | 0.90 | EGFR (0.49) | EGFRRPS6KB1CRHR1IGF1RHDAC4 | |
| SCHEMBL481859 | 0.86 | EGFR (0.48) | EGFRRPS6KB1LDHALDHB | |
| SCHEMBL481858 | 0.86 | EGFR (0.48) | EGFRRPS6KB1LDHALDHB | |
| SCHEMBL481865 | 0.86 | EGFR (0.48) | EGFRRPS6KB1LDHALDHB | |
| SCHEMBL481775 | 0.82 | LDHB (0.57) | EGFRLDHALDHB | |
| SCHEMBL481774 | 0.82 | LDHB (0.57) | EGFRLDHALDHB | |
| SCHEMBL482107 | 0.82 | LDHB (0.57) | EGFRLDHALDHB | |
| SCHEMBL481627 | 0.81 | LDHB (0.46) | LDHALDHBHDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2457913-B1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARM LLC (US) | 2017-04-19 | — | — | EP | disclosed |
| EP-2090577-B1 | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | SIGNAL PHARM LLC (US) | 2017-04-05 | — | — | EP | disclosed |
| US-8372976-B2 | Methods of treatment comprising the administration of heteroaryl compounds | SIGNAL PHARMACEUTICALS, LLC (US) | 2013-02-12 | — | — | US | disclosed |
| EP-2457913-A2 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | Signal Pharmaceuticals LLC (US) | 2012-05-30 | — | — | EP | disclosed |
| EP-2090577-A2 | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | Signal Pharmaceuticals LLC (US) | 2009-08-19 | — | — | EP | disclosed |
| EP-2078016-A2 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals LLC (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20090023724-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2009-01-22 | — | — | US | disclosed |
| WO-2008051493-A2 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023724-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | JAK2, PHKG1, PHKG2 | EGFR 1009/4885RPS6KB1 45/4885LDHA 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.